NCT06888687Active, not recruiting
Comparison of Dietetics Support With and Without Continuous Glucose Monitoring in Individuals With Type 2 Diabetes.
Continuous Glucose Monitoring-Assisted Remote E-health Dietetics to Empower People With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 160 (actual)
- First submitted
- 10 Mar 2025
- Start date
- 12 May 2025
- Primary completion date
- 28 Nov 2026
- Lead sponsor
- Australian Catholic University
- Diseases
- Type 2 diabetes
- NCT number
- NCT06888687
What you commit to
- Study type: Interventional
- Participants enrolled: 160
- From 12 May 2025 to the primary completion date, 28 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Change of antihyperglcyaemic medications within last three months
Other illness
- Eating Disorder Examination Questionnaire (EDE-Q) global score \>2.8 OR global score \> or equal to 1.52, with sum of Q14-18 \> or equal to 4
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
Lab values
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
Age
- Under the age of 18 years
Other
- Use of CGM within the last six months
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (\>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Women who are pregnant or breastfeeding (within 24 weeks)
Who the study is looking for
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Australian Catholic University Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.